We are live on ! Find out more
CRBP icon

Corbus Pharmaceuticals
CRBP

107 hedge funds and large institutions have $486M invested in Corbus Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 41 funds opening new positions, 23 increasing their positions, 24 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

173% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 15

100% more funds holding in top 10

Funds holding in top 10: 3 → 6 (+3)

45% more capital invested

Capital invested by funds: $335M → $486M (+$151M)

30% more funds holding

Funds holding: 82 → 107 (+25)

19.27% more ownership

Funds ownership: 81.31% → 100.59% (+19%)

4% less repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 24

22% less call options, than puts

Call options by funds: $1.19M | Put options by funds: $1.52M

Holders
107
Holders Change
+25
Holders Change %
+30.49%
% of All Funds
1.55%
Holding in Top 10
6
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+100%
% of All Funds
0.09%
New
41
Increased
23
Reduced
24
Closed
15
Calls
$1.19M
Puts
$1.52M
Net Calls
-$331K
Net Calls Change
-$438K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$22.7M
2
State Street
State Street
Massachusetts
+$17.1M
3
DGM
Darwin Global Management
Jersey
+$13.7M
4
SCM
Sio Capital Management
New York
+$9.47M
5
APM
Avidity Partners Management
Texas
+$9.07M

Top Sellers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$20.4M
2
IC
Ikarian Capital
Texas
-$10.5M
3
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$5.71M
4
PM
Prosight Management
Texas
-$3.95M
5
Barclays
Barclays
United Kingdom
-$3.93M
Name Holding Trade Value Shares
Change 		Change in
Stake
SC
26
Stempoint Capital
New York
$4.59M +$4.27M +101,479 New
IHAM
27
Integral Health Asset Management
New York
$4.53M +$4.21M +100,000 New
Barclays
28
Barclays
United Kingdom
$4.15M -$3.93M -93,420 -50%
BFM
29
Boothbay Fund Management
New York
$3.91M -$2.93M -69,664 -45%
EAM
30
Exome Asset Management
New York
$3.84M -$129K -3,056 -3%
Verition Fund Management
31
Verition Fund Management
Connecticut
$3.3M +$3.06M +72,842 New
Schroder Investment Management Group
32
Schroder Investment Management Group
United Kingdom
$2.92M – – –
ACP
33
Acuta Capital Partners
California
$2.92M +$2.71M +64,500 New
DCM
34
Driehaus Capital Management
Illinois
$2.85M – – –
Goldman Sachs
35
Goldman Sachs
New York
$2.74M -$1.93M -45,850 -43%
SCM
36
Superstring Capital Management
New York
$2.56M +$2.38M +56,468 New
Bank of America
37
Bank of America
North Carolina
$2.4M +$1.06M +25,092 +90%
CCM
38
Cinctive Capital Management
New York
$2.22M +$2.06M +49,013 New
Ensign Peak Advisors
39
Ensign Peak Advisors
Utah
$2.05M -$931K -22,136 -33%
WC
40
Wexford Capital
Florida
$2M +$1.86M +44,156 New
Hudson Bay Capital Management
41
Hudson Bay Capital Management
Connecticut
$1.95M – – –
TD Asset Management
42
TD Asset Management
Ontario, Canada
$1.85M +$824K +19,600 +92%
HP
43
HealthInvest Partners
Sweden
$1.77M +$46.3K +1,100 +3%
HS
44
HighVista Strategies
Massachusetts
$1.76M +$1.63M +38,793 New
NIM
45
NEOS Investment Management
Connecticut
$1.65M +$1.53M +36,455 New
TI
46
Trexquant Investment
Connecticut
$1.5M +$891K +21,180 +177%
Bank of New York Mellon
47
Bank of New York Mellon
New York
$1.37M +$1.27M +30,236 New
Mirae Asset Global ETFs Holdings
48
Mirae Asset Global ETFs Holdings
Hong Kong
$1.36M +$1.27M +30,124 New
Charles Schwab
49
Charles Schwab
California
$1.31M +$1.21M +28,843 New
N
50
Nuveen
North Carolina
$1.26M +$1.17M +27,898 New
1
2
3 4 5

CRBP Hedge Fund Activity: Q2 2024 in Review

107 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q2 2024, worth a combined $486M — up 45% from $335M a quarter earlier.

Buyers outnumbered sellers: 41 funds opened new CRBP positions and 15 closed out — a net gain of 26 holders — while 23 added to existing stakes and 24 trimmed.

The largest buyer was BlackRock, adding an estimated $22.7M. The largest seller was Point72 Asset Management, cutting an estimated $20.4M.

  • 107 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q2 2024, up from 82 in Q1 2024.
  • Funds reported $486M of Corbus Pharmaceuticals stock for Q2 2024, up 45% quarter-over-quarter.
  • 41 funds opened new Corbus Pharmaceuticals positions in Q2 2024 and 15 closed out, a net change of +26 holders.
  • The largest Corbus Pharmaceuticals buyer in Q2 2024 was BlackRock, an estimated $22.7M added.
  • The largest Corbus Pharmaceuticals seller in Q2 2024 was Point72 Asset Management, an estimated $20.4M sold.

Based on aggregated 13F filings for Q2 2024.